Extreme boom-and-bust cycles leave early-stage biotechs stranded in the preclinical-to-clinical 'valley of death,' as private VC capital gravitates overwhelmingly toward late-stage or software AI. To counter strategic risks—such as China securing two-thirds of global pharma licensing—the US needs an apolitical sovereign biotech wealth fund modeled after Singapore. To preserve disciplined capital allocation, the fund should co-invest exclusively alongside the world's top 10% performing venture capital firms.

Despite the NIH budget more than tripling since 1998, the U.S. has not seen a proportional rise in breakthroughs, a phenomenon known as Eroom's Law. The core issue isn't the amount of money, but a lack of innovation in how science is funded and conducted, with incentives that discourage risk.

An economic analysis modeling a 40% smaller NIH budget from 1980-2007 found that foundational science supporting major drugs like Gilead's HIV meds and Novartis's Gleevec would not have been funded. This provides a stark, data-driven warning about the long-term innovation cost of current budget cut proposals.

The most significant long-term risk to US biotech isn't foreign competition but the degradation of its basic research environment. This system attracts top global talent, and its decline will have ramifications for decades.

The market is currently ignoring the long-term impact of deep cuts to research funding at agencies like the NIH. While effects aren't immediate, this erosion of foundational academic science—the "proving ground" for new discoveries—poses a significant downstream risk to the entire biotech and pharma innovation pipeline.

While China is a rising competitor, the real danger to America's biotech leadership is the weakening of its own foundational pillars. Eroding NIH funding, restrictive immigration for top talent, and inefficient regulatory processes pose a greater risk than any single foreign nation.

The greatest threat to US innovation is not simply cutting NIH funding, but imposing political litmus tests on which research gets funded. This mirrors the disastrous Lysenkoism of the Soviet Union, where political ideology replaced the scientific method, guaranteeing the destruction of true innovation.

The foundational U.S. science policy was created in 1945 when the government funded 70% of all R&D. Today, that ratio has inverted, with industry funding 70%. This dramatic shift requires a new government strategy focused on funding only the basic, pre-competitive research that the private sector won't.

Ovid's Dr. Jeremy Levin argues that the convergence of public distrust in science, politicized funding, and agency turmoil represents a fundamental, structural threat. Unlike past cyclical downturns that eventually recover, these changes could permanently harm the US biotech ecosystem if they are not addressed directly.